Premium
Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma
Author(s) -
Abramson Jeremy S.,
Irwin Kelly E.,
Frigault Matthew J.,
Dietrich Jorg,
McGree Brianne,
Jordan Justin T.,
Yee Andrew J.,
Chen YiBin,
Raje Noopur S.,
Barnes Jeffrey A.,
Davis Benjamin
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32411
Subject(s) - medicine , chimeric antigen receptor , refractory (planetary science) , lymphoma , cd19 , b cell , human immunodeficiency virus (hiv) , oncology , chemotherapy , clinical trial , immunology , antigen , immunotherapy , cancer , antibody , physics , astrobiology
HIV‐positive patients have been excluded from clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapies. Herein, the authors report on 2 patients with HIV/AIDS–associated, chemotherapy‐refractory, aggressive B‐cell lymphomas who were treated successfully with the anti‐CD19 CAR T‐cell product axicabtagene ciloleucel.